4. Wieser H.: Relation between gliadin structure and coeliac toxicity. Acta Paediatr., Suppl. 1996, May; 412: 3-9.
5. Morita E., Matsuo H., Mihara S., et al.: Fast omega-gliadin is a major allergen in wheat-dependent exercise-induced anaphylaxis. J. Dermatol. Sci., 2003 Nov; 33, 2; 99-104.
10. Gluten epitopes in coeliac disease, http://immunology.no/cd/eu.
11. Jennings J.S.R., Howdle P.D.: New development in celiac disease. Curr. Opin. Gastroenterol., 2003, 19; 118-129.
12. Hayday A., Theodoridis E., Ramsburg E., et al.: Intraepithelial lymphocytes: exploring the hird way in immunology. Nat. Immunol., 2001, 2; 997-1003.
13. Anderson R.P., Degano P., Godkin A.J., et al.: In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat. Med., 2000, 6; 337-342.
14. Arentz-Hansen H., Korner R., Molberg O., et al.: The intestinal T cell response to α-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J. Exp. Med., 2000, 191; 603-612.
15. Pastor M.T., Diez A., Perez-Paya E., et al.: Addressing substrate glutamine requirements for tissue transglutaminase using substance P analogues. FEBS Lett., 1999, 451; 231-234.
16. Fraser J.S., Engel W., Ellis H.J., et al.: Coeliac disease: in vivo toxicity of the putative immunodominant epitope. Gut. 2003 Dec, 52, 12; 1698-702.
17. Martucci S., Biagi F., Di Sabatino A., et al.: Coeliac disease. Dig. Liver. Dis., 2002 Sep, 34 Suppl. 2; S150-3.
18. Martucci S., Fraser J.S., Biagi F., et al.: Characterizing one of the DQ2 candidate epitopes in coeliac disease: A-gliadin 51-70 toxicity assessed using an organ culture system. Eur. J. Gastroenterol. Hepatol., 2003, 15, 12; 1293-8.
19. Vader W., Kooy Y., Van Veelen P., et al.: The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. Gastroenterology 2002, 122; 1729-1737.
20. Qiao S.W., Bergseng E., Molberg O., et al.: Antigen presentation to celiac lesion-derived T cells of a 33-mer gliadin peptide naturally formed by gastrointestinal digestion. J Immunol. 2004, Aug 1, 173, 3; 1757-62.
21. Maiuri L., Ciacci C., Ricciardelli I., et al.: Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet, 2003, 362; 30-37.
22. Rivabene R., Mancini E., De Vincenzi M.: In vitro cytotoxic effect of wheat gliadin-derived peptides on the Caco-2 intestinal cell line is associated with intracellular oxidative imbalance: implications for coeliac disease. Biochim. Biophys. Acta., 1999 Jan 6,1453, 1; 152-60.
23. Senrad C.E.: Celiac disease and gluten sensitivity. www.gluten.net.
24. Stec-Michlska K., Chojnacki J.: Celiakia - zapomniana choroba u dorosłych. Terapia, 2005, 6; 35-37.
25. Collino L.: Prevalence of celiac disease increased in cardiomyopathy. Lancet, 1999, 354; 222-223.
26. Dohan F.C.: Celiac disease as a model for schizofrenia. Biol. Psychiatry., 1983, 188; 561- 564.
29. D’Archivio M., Silano M., Fagnan C., et al.: Clinical evolution of celiac disease in Italy 1982-2002. J.Clin. Gastroenterol., 2004, 38; 877-879.
30. Sanders D.S., Patel D., Stephenson T.J., et al.: A primary care cross-sectional study of undiagnosed adult coeliac disease. Eur. J. Gastroenterol. Hepatol., 2003, 15; 407-413.
32. Matysiak-Budnik T., Candalh C., Cellier C., et. al.: Limited efficiency of propyl-endopeptiase in the detoxification of gliadin peptides of celiac disease. Gastroenterol., 2005, 129; 786-796.
33. De Angelis M., Rizello C.G., Fasano A., et al.: VSL# probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for celiac sprue. Biochim. Biophys. Acta, 2006, 1762; 80-93.